Effect of L. Reuteri on Bowel Movements in Children (BIOWELL Study) (BIOWELL)
Primary Purpose
Constipation
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
L.reuteri
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Constipation focused on measuring constipation, Lactobacillus reuteri, probiotics
Eligibility Criteria
Inclusion Criteria:
- Age: 6 months up to 4 years
- Suffering from functional constipation, as defined by modified Rome III criteria for children aged 4 years or less (Hyman 2006)
- Parent(s) willingness to postpone major changes in the infant feeding mode
- Parent(s) willingness and ability to fill in diary and questionnaires
- Written informed consent from parents
- Stated availability throughout the study period
Exclusion Criteria:
- Chronic illness or major medical problem
- Gastrointestinal disease (including organic cause of constipation and dyschezia or history of severe fecalome)
- Intractable constipation (not responding to conventional treatment for more than 3 months)
- Gastrointestinal surgery (in the year before enrolment)
- Food allergy, lactose or gluten intolerance, as declared by parents
- Use of L. reuteri two weeks before randomisation and throughout the intervention period. If fed with infant formula, it cannot contain L. reuteri.
- Use of antibiotics two weeks before randomisation and throughout the intervention period, both infant/child and lactating mother
- If breastfeeding, use of L reuteri by the mother 2 weeks prior to enrolment
- Conventional treatment for constipation within 2 weeks before enrolment
- Medication that influences gastrointestinal motility
- Mental or behavioral disorders as judged by the investigator
Sites / Locations
- CH Sud francilien
- CHI Creteil
- Hôpital J. Monod - Pavillon Femme Mère Enfant - Le Havre
- Hôpital Saint Vincent-de-Paul
- CHU Robert Debré
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
L.reuteri
Placebo
Arm Description
probiotics: L.reuteri produced by Biogaia 5 drops per day: 10exp(8) colony forming unit will be delivered
Same formulation as probiotics, without active substance. 5 drops per day will be delivered
Outcomes
Primary Outcome Measures
Change in number of spontaneous bowel movements
Change in number of spontaneous bowel movements at week 4 compared to baseline evaluated by a bowel habit questionnaire (BQH)
Secondary Outcome Measures
rescue medication
Total number of rescue medication during the intervention period
fecal retention
number of subjects with 3 or more than 3 stools per week and without fecal retention at the last week of the intervention period
weekly number of spontaneous bowel movements
weekly number of spontaneous bowel movements evaluated by the Bowel habit Questionnaire
weekly number of spontaneous bowel movements
weekly number of spontaneous bowel movements evaluated by the Bowel habit Questionnaire
weekly number of spontaneous bowel movements
weekly number of spontaneous bowel movements evaluated by the Bowel habit Questionnaire
weekly number of spontaneous bowel movements
weekly number of spontaneous bowel movements evaluated by the Bowel habit Questionnaire
weekly number of spontaneous bowel movements
weekly number of spontaneous bowel movements evaluated by the Bowel habit Questionnaire
Score of QOL
Score of quality of life measured using the PedsQL Parent family acute version
Score of QOL
Score of quality of life measured using the PedsQL Parent family acute version
Score of QOL
Score of quality of life measured using the PedsQL Parent family acute version
Pain during defecation
Score of pain during defecation measured using Hick or Wong baker faces
Pain during defecation
Score of pain during defecation measured using Hick or Wong baker faces
Pain during defecation
Score of pain during defecation measured using Hick or Wong baker faces
Full Information
NCT ID
NCT03030664
First Posted
January 23, 2017
Last Updated
June 9, 2022
Sponsor
Centre Hospitalier Intercommunal Creteil
Collaborators
BioGaia AB
1. Study Identification
Unique Protocol Identification Number
NCT03030664
Brief Title
Effect of L. Reuteri on Bowel Movements in Children (BIOWELL Study)
Acronym
BIOWELL
Official Title
Randomised Controlled Trial With Two Parallel Arms Testing the Effect of L. Reuteri on Bowel Movements in Children Aged 6 Months to 4 Years
Study Type
Interventional
2. Study Status
Record Verification Date
June 2022
Overall Recruitment Status
Completed
Study Start Date
March 1, 2017 (Actual)
Primary Completion Date
June 30, 2021 (Actual)
Study Completion Date
July 30, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Centre Hospitalier Intercommunal Creteil
Collaborators
BioGaia AB
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
A randomized, multicenter, placebo-controlled, double blind study in two parallel groups testing the efficacy of daily oral supplementation with the probiotic L.reuteri DSM17938 compared to placebo in increasing the number of spontaneous bowel movements in infants and children with functional constipation.
Detailed Description
Functional constipation in infants up to 4 years of age is defined according to Rome III criteria (Hyman 2006). The diagnose must include 1 month of at least two of the following criteria: two or fewer defecations per week; at least 1 episode per week of incontinence after the acquisition of toilet skills; history of excessive stool retention; history of painful or hard bowel movements; presence of a large faecal mass in the rectum; history of large-diameter stools that may obstruct the toilet.
Accompanying symptoms may include irritability, decreased appetite and/or early satiety. The accompanying symptoms disappear immediately following passage of a large stool.
There is a growing interest for the use of probiotics in functional constipation as research suggests that probiotics could provide beneficial support in the traditional treatment arsenal although the mechanisms of actions are not completely understood.
Wu et al have demonstrated that Lactobacillus reuteri DSM 17938 may have a region-specific intestinal effect on gut motility and therefore could be beneficial in treatment of constipation
Lactobacillus reuteri DSM 17938 has shown significant favourable effects in adults (Ojetti 2014) and young children as described above (Coccorullo 2010, Olgac 2013). These studies require confirmation however. The present clinical study has been designed to strengthen the current available data that L. reuteri DSM 17938 has beneficial effects in infants and young children with functional constipation.
We hypothesize that daily oral supplementation with the probiotic Lactobacillus reuteri DSM 17938 will effectively increase the number of spontaneous bowel movements in infants/children diagnosed with functional constipation according to Rome IV.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Constipation
Keywords
constipation, Lactobacillus reuteri, probiotics
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
52 (Actual)
8. Arms, Groups, and Interventions
Arm Title
L.reuteri
Arm Type
Active Comparator
Arm Description
probiotics: L.reuteri produced by Biogaia 5 drops per day: 10exp(8) colony forming unit will be delivered
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Same formulation as probiotics, without active substance. 5 drops per day will be delivered
Intervention Type
Dietary Supplement
Intervention Name(s)
L.reuteri
Other Intervention Name(s)
Lactobacillus reuteri
Intervention Description
Each day, at about the same time, the subjects will be given 5 drops (1x10^8 CFU) of the study product in connection with feeding
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Same formulation as study product, without probiotics.
Primary Outcome Measure Information:
Title
Change in number of spontaneous bowel movements
Description
Change in number of spontaneous bowel movements at week 4 compared to baseline evaluated by a bowel habit questionnaire (BQH)
Time Frame
Week 4
Secondary Outcome Measure Information:
Title
rescue medication
Description
Total number of rescue medication during the intervention period
Time Frame
week 4
Title
fecal retention
Description
number of subjects with 3 or more than 3 stools per week and without fecal retention at the last week of the intervention period
Time Frame
week 4
Title
weekly number of spontaneous bowel movements
Description
weekly number of spontaneous bowel movements evaluated by the Bowel habit Questionnaire
Time Frame
week 1
Title
weekly number of spontaneous bowel movements
Description
weekly number of spontaneous bowel movements evaluated by the Bowel habit Questionnaire
Time Frame
week 2
Title
weekly number of spontaneous bowel movements
Description
weekly number of spontaneous bowel movements evaluated by the Bowel habit Questionnaire
Time Frame
week 3
Title
weekly number of spontaneous bowel movements
Description
weekly number of spontaneous bowel movements evaluated by the Bowel habit Questionnaire
Time Frame
week 4
Title
weekly number of spontaneous bowel movements
Description
weekly number of spontaneous bowel movements evaluated by the Bowel habit Questionnaire
Time Frame
week 8
Title
Score of QOL
Description
Score of quality of life measured using the PedsQL Parent family acute version
Time Frame
baseline
Title
Score of QOL
Description
Score of quality of life measured using the PedsQL Parent family acute version
Time Frame
week 4
Title
Score of QOL
Description
Score of quality of life measured using the PedsQL Parent family acute version
Time Frame
week 8
Title
Pain during defecation
Description
Score of pain during defecation measured using Hick or Wong baker faces
Time Frame
baseline
Title
Pain during defecation
Description
Score of pain during defecation measured using Hick or Wong baker faces
Time Frame
week 4
Title
Pain during defecation
Description
Score of pain during defecation measured using Hick or Wong baker faces
Time Frame
week 8
10. Eligibility
Sex
All
Minimum Age & Unit of Time
6 Months
Maximum Age & Unit of Time
4 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age: 6 months up to 4 years
Suffering from functional constipation, as defined by modified Rome III criteria for children aged 4 years or less (Hyman 2006)
Parent(s) willingness to postpone major changes in the infant feeding mode
Parent(s) willingness and ability to fill in diary and questionnaires
Written informed consent from parents
Stated availability throughout the study period
Exclusion Criteria:
Chronic illness or major medical problem
Gastrointestinal disease (including organic cause of constipation and dyschezia or history of severe fecalome)
Intractable constipation (not responding to conventional treatment for more than 3 months)
Gastrointestinal surgery (in the year before enrolment)
Food allergy, lactose or gluten intolerance, as declared by parents
Use of L. reuteri two weeks before randomisation and throughout the intervention period. If fed with infant formula, it cannot contain L. reuteri.
Use of antibiotics two weeks before randomisation and throughout the intervention period, both infant/child and lactating mother
If breastfeeding, use of L reuteri by the mother 2 weeks prior to enrolment
Conventional treatment for constipation within 2 weeks before enrolment
Medication that influences gastrointestinal motility
Mental or behavioral disorders as judged by the investigator
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marc BELLAICHE, MD
Organizational Affiliation
Hopital Universitaire Robert-Debre
Official's Role
Principal Investigator
Facility Information:
Facility Name
CH Sud francilien
City
Corbeil-Essonnes
Country
France
Facility Name
CHI Creteil
City
Créteil
ZIP/Postal Code
94000
Country
France
Facility Name
Hôpital J. Monod - Pavillon Femme Mère Enfant - Le Havre
City
Le Havre
Country
France
Facility Name
Hôpital Saint Vincent-de-Paul
City
Lille
Country
France
Facility Name
CHU Robert Debré
City
Paris
Country
France
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
36389355
Citation
Jung C, Kalach N, Degas V, Jeridi Y, Bertrand V, Bellaiche M. Effect of L. reuteri on bowel movements in children aged 6 months to 4 years: A double-blind randomized controlled trial. Front Pediatr. 2022 Oct 26;10:997104. doi: 10.3389/fped.2022.997104. eCollection 2022.
Results Reference
derived
Learn more about this trial
Effect of L. Reuteri on Bowel Movements in Children (BIOWELL Study)
We'll reach out to this number within 24 hrs